Combining immunotherapy and epidermal growth factor receptor kinase inhibitors: worth the risk?

Immunotherapy has improved survival in advanced non-small cell lung cancer (NSCLC) and offers the potential for meaningful, durable responses in a subset of patients. Ongoing efforts are focused on extending these benefits to more patients.